Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Hop S. Tran Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8612-8272; OpenAlex author ID A5021139165. Sources: OpenAlex.

Their work

Papers
18 (first author 7, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 18

  1. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002608↗
  2. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  3. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  4. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000005249↗
  5. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Last author DOI 10.1245/s10434-021-10709-4↗
  6. ASO Author Reflections: The Challenge of Achieving High-Quality, Equitable Care for Pancreatic Cancer: Might Medicaid Expansion Be a Piece of the Puzzle? Last author DOI 10.1245/s10434-021-10713-8↗
  7. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysi… First author DOI 10.1245/s10434-020-09327-3↗
  8. Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet? First author DOI 10.1001/jamaoncol.2020.0562↗
  9. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. First author DOI 10.1016/j.surg.2018.08.003↗
  10. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Last author DOI 10.1016/j.surg.2018.12.009↗
  11. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Co-author DOI 10.1016/j.surg.2017.05.003↗
  12. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Co-author DOI 10.3390/nu9030243↗
  13. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cance… Co-author DOI 10.1007/s11605-013-2374-3↗
  14. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and surviva… First author DOI 10.1007/s11605-013-2412-1↗
  15. Therapeutic advances in pancreatic cancer. First author DOI 10.1053/j.gastro.2013.01.078↗
  16. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Co-author DOI 10.5754/hge11836↗
  17. Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. First author DOI 10.1002/ijc.25942↗
  18. Submillimeter-resolution fluorescence laparoscopy of pancreatic cancer in a carcinomatosis mouse model visualizes metastases not seen with standard laparoscopy. Co-author DOI 10.1089/lap.2011.0181↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nader Nabile Massarweh · 7 shared papers, 2017–2022 · strength 0.92
  2. Ching-Wei David Tzeng · 5 shared papers, 2014–2026 · strength 0.81
  3. Matthew H. G. Katz · 6 shared papers, 2014–2026 · strength 0.75
  4. Naruhiko Ikoma · 3 shared papers, 2023–2026 · strength 0.61
  5. Michael P. Kim · 3 shared papers, 2023–2026 · strength 0.61
  6. Wilson Luiz da Costa · 3 shared papers, 2020–2022 · strength 0.57
  7. Jeffrey E. Lee · 4 shared papers, 2014–2026 · strength 0.52
  8. Timothy Eric Newhook · 2 shared papers, 2023–2026 · strength 0.45
  9. Fabian Mc. Johnston · 2 shared papers, 2022 · strength 0.43
  10. Annabelle L. Fonseca · 2 shared papers, 2022 · strength 0.43
  11. Rebecca Anne Snyder · 1 shared paper, 2026 · strength 0.28
  12. Jean‐Nicolas Vauthey · 3 shared papers, 2014–2023 · strength 0.24
  13. Eric Jay Silberfein · 3 shared papers, 2017–2019 · strength 0.22
  14. George Van Buren · 3 shared papers, 2017–2019 · strength 0.22
  15. Yongwoo David Seo · 1 shared paper, 2023 · strength 0.17
  16. Yun Shin Chun · 1 shared paper, 2023 · strength 0.17
  17. Martin J. Heslin · 1 shared paper, 2022 · strength 0.16
  18. William E. Fisher · 2 shared papers, 2017–2019 · strength 0.16
  19. Suyu Liu · 1 shared paper, 2024 · strength 0.16
  20. Albert C. Koong · 1 shared paper, 2024 · strength 0.16
  21. Jason A. Willis · 1 shared paper, 2024 · strength 0.16
  22. Ramez Kouzy · 1 shared paper, 2024 · strength 0.16
  23. Grace L. Smith · 1 shared paper, 2024 · strength 0.16
  24. Christopher Shi · 1 shared paper, 2024 · strength 0.16
  25. Cullen M. Taniguchi · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.